Statements in which the resource exists.
SubjectPredicateObjectContext
pubmed-article:12588385rdf:typepubmed:Citationlld:pubmed
pubmed-article:12588385lifeskim:mentionsumls-concept:C0033774lld:lifeskim
pubmed-article:12588385lifeskim:mentionsumls-concept:C0008976lld:lifeskim
pubmed-article:12588385lifeskim:mentionsumls-concept:C0034656lld:lifeskim
pubmed-article:12588385lifeskim:mentionsumls-concept:C0022646lld:lifeskim
pubmed-article:12588385lifeskim:mentionsumls-concept:C0061851lld:lifeskim
pubmed-article:12588385pubmed:issue2lld:pubmed
pubmed-article:12588385pubmed:dateCreated2003-2-17lld:pubmed
pubmed-article:12588385pubmed:abstractTextRenal itch is a relatively common and distressing problem for patients with chronic renal failure. Ondansetron, a serotonin type 3 receptor antagonist was developed for relief of chemotherapy induced nausea. Recently, anecdotal reports describe relief of renal itch with ondansetron.lld:pubmed
pubmed-article:12588385pubmed:languageenglld:pubmed
pubmed-article:12588385pubmed:journalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12588385pubmed:citationSubsetIMlld:pubmed
pubmed-article:12588385pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12588385pubmed:chemicalhttp://linkedlifedata.com/r...lld:pubmed
pubmed-article:12588385pubmed:statusMEDLINElld:pubmed
pubmed-article:12588385pubmed:monthFeblld:pubmed
pubmed-article:12588385pubmed:issn0007-0963lld:pubmed
pubmed-article:12588385pubmed:authorpubmed-author:MurphyMMlld:pubmed
pubmed-article:12588385pubmed:authorpubmed-author:EGANJ RJRlld:pubmed
pubmed-article:12588385pubmed:authorpubmed-author:PalSSlld:pubmed
pubmed-article:12588385pubmed:authorpubmed-author:CarmichaelA...lld:pubmed
pubmed-article:12588385pubmed:authorpubmed-author:ReaichDDlld:pubmed
pubmed-article:12588385pubmed:issnTypePrintlld:pubmed
pubmed-article:12588385pubmed:volume148lld:pubmed
pubmed-article:12588385pubmed:ownerNLMlld:pubmed
pubmed-article:12588385pubmed:authorsCompleteYlld:pubmed
pubmed-article:12588385pubmed:pagination314-7lld:pubmed
pubmed-article:12588385pubmed:dateRevised2006-11-15lld:pubmed
pubmed-article:12588385pubmed:meshHeadingpubmed-meshheading:12588385...lld:pubmed
pubmed-article:12588385pubmed:meshHeadingpubmed-meshheading:12588385...lld:pubmed
pubmed-article:12588385pubmed:meshHeadingpubmed-meshheading:12588385...lld:pubmed
pubmed-article:12588385pubmed:meshHeadingpubmed-meshheading:12588385...lld:pubmed
pubmed-article:12588385pubmed:meshHeadingpubmed-meshheading:12588385...lld:pubmed
pubmed-article:12588385pubmed:meshHeadingpubmed-meshheading:12588385...lld:pubmed
pubmed-article:12588385pubmed:meshHeadingpubmed-meshheading:12588385...lld:pubmed
pubmed-article:12588385pubmed:meshHeadingpubmed-meshheading:12588385...lld:pubmed
pubmed-article:12588385pubmed:meshHeadingpubmed-meshheading:12588385...lld:pubmed
pubmed-article:12588385pubmed:meshHeadingpubmed-meshheading:12588385...lld:pubmed
pubmed-article:12588385pubmed:meshHeadingpubmed-meshheading:12588385...lld:pubmed
pubmed-article:12588385pubmed:meshHeadingpubmed-meshheading:12588385...lld:pubmed
pubmed-article:12588385pubmed:year2003lld:pubmed
pubmed-article:12588385pubmed:articleTitleA randomized, placebo-controlled, double-blind trial of ondansetron in renal itch.lld:pubmed
pubmed-article:12588385pubmed:affiliationDepartment of Dermatology, South Cleveland Hospital, Middlesbrough, TS4 3BW, UK. drmichellemurphy@eircom.netlld:pubmed
pubmed-article:12588385pubmed:publicationTypeJournal Articlelld:pubmed
pubmed-article:12588385pubmed:publicationTypeClinical Triallld:pubmed
pubmed-article:12588385pubmed:publicationTypeRandomized Controlled Triallld:pubmed
pubmed-article:12588385pubmed:publicationTypeResearch Support, Non-U.S. Gov'tlld:pubmed
pubmed-article:12588385pubmed:publicationTypeMulticenter Studylld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12588385lld:pubmed
http://linkedlifedata.com/r...pubmed:referesTopubmed-article:12588385lld:pubmed